Aristotle University Of Thessaloniki (AUTH)
Μελέτη της επίδρασης της δαπαγλιφλοζίνης στην 24ωρη αορτική πίεση την αρτηριακή σκληρία και τη λευκωματινουρία σε ασθενείς με σακχαρώδη διαβήτη τύπου 2
Abstract
dc:descriptionSUMMARY AND CONCLUSIONS: Diabetes mellitus (DM) is major issue of public health, with an estimatedprevalence of 9% in adults. Diabetes is a major cardiovascular risk factor; longitudinalstudies suggest that about 50% of deaths in DM due to cardiac causes, including suddendeath, myocardial infraction, stroke or decompensated heart failure. The mechanisticbackground defining the association between DM and cardiovascular events is complex.The co-existence of type-2 DM and hypertension has been long established in thecontext of the metabolic syndrome; >90% of type-2 DM patients are hypertensive, a factleading to further increase in cardiovascular risk. Accelerated arteriosclerosis andreduced arterial compliance, which are commonly present in patients with impairedglucose tolerance or type-2 DM are among the major pathogenetic mechanisms foradverse outcomes in these patients.Arterial stiffness and increased central systolic blood pressure (BP) areestablished risk factors in the general population, as well as in patients with hypertensionor DM. Arterial stiffness reflects structural and functional changes in viscoelasticproperties of the arterial wall, leading to impairment of large artery cushioning function.The major consequence of arterial stiffness is the early return of the reflected wave fromthe periphery to the ascending aorta (during systole rather diastole), resulting inaugmentation of aortic systolic blood pressure (SBP) and pulse pressure (PP). Therefore,arterial stiffness is considered the principal pathogenetic mechanism for isolated systolichypertension, and plays a major role in the development of left ventricular hypertrophyand sudden cardiac death. Accumulated evidence suggests that among patients with DM,arterial stiffness assessed with the use of aortic pulse wave velocity (PWV),augmentation index (AIx) and pulse pressure (PP) represents a strong and independentpredictor of all-cause and cardiovascular mortality.Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, are a relatively novelhypoglycemic oral drug class for the management of type-2 DM. These agents act in theproximal renal tubule and reduce glucose reabsorption, producing mild glycosuria, whilethey also have mild natriuretic and diuretic effects. During the past years, major clinicaltrials showed that SGLT-2 inhibitors are able to potently decrease cardiovascular events, new-onset heart failure, progression of renal disease and all-cause mortality. Among themechanisms that were originally proposed to be involved in these beneficial effects, decrease in BP, body weight, uric acid, volume overload and arterial stiffness had aprominent place. The contribution of several of the above mechanisms in the cardio- andnephroprotective actions of these drugs are currently under examination. Until the design of this thesis, no previous study had ever evaluated the effects ofan SGLT-2 inhibitor on ambulatory aortic BP and ambulatory arterial stiffnessparameters in patients with type-2 DM. The main aim of the present study was toinvestigate the effects of dapagliflozin on ambulatory aortic BP in patients with type-2DM. Secondary aims were to investigate the effects of dapagliflozin on ambulatoryarterial stiffness parameters and urine albumin excretion.The present study involved a total of 85 patients fulfilling the inclusion andexclusion criteria. All eligible patientss underwent a full clinical and laboratoryevaluation at baseline, including a 24-h ambulatory BP monitoring (ABPM) with MobilO-Graph device. Following the baseline evaluation, subjects were randomized in a 1:1ratio in the active group (dapagliflozin 10 mg/24h) (N=43) and in the placebo group(N=42). At 6 weeks, a telephone visit was performed to discuss possible occurrence ofadverse events. At 12 weeks (study-end), patients were evaluated again, undergoing allprocedures described above for baseline evaluation, including 24-h ABPM. This doctoral thesis had several important findings. In the dapagliflozin group,24-hour SBP (129.0±12.6 vs 123.2±12.4; p<0.001), DBP (77.3±7.3 vs 75.1±6.4;p=0.008) and PP levels (51.6±10.8 vs 48.1±10.9, p=0.001) reduced from baseline tostudy-end, but did not change in the placebo group. The reduction in 24-h SBP levelswas greater in the dapagliflozin group compared with the placebo group (dapagliflozin: -5.80±9.48 vs placebo: -0.10±8.70 mmHg; p=0.005). The relevant difference between groups for change in 24-hour DBP was borderline significant (-2.23±5.26 vs 0.10±5.70;p=0.054). These changes were accompanied by a significantly higher reduction in 24-hour PP levels (dapagliflozin: -3.57±6.67 vs placebo: -0.21±6.31; p=0.019) withdapagliflozin compared to placebo. There were not any differences in 24-hour HRchanges between groups. With regards to 24-h aortic BP, 12-week treatment with dapagliflozin reduced24-h aortic SBP (117.4±10.5 vs 113.3±8.8; p=0.002). DBP (78.9±7.3 vs: 77.3±6.5;p=0.047) and PP levels (38.53±7.44 vs 36.05±6.59; p=0.004). No significant differencesin 24-h aortic BP levels between baseline and study-end were noted for the placebogroup. With regards to the differences in Delta 24-h aortic SBP, there was a greaterreduction in the dapagliflozin compared to the placebo group (-4.12±8.00 vs -0.65±7.77;p=0.046). The mean change of 24-h aortic DBP was not significantly different betweenthe two study groups (dapagliflozin: -1,63±5,23 vs placebo: 0,16±5,99, p=0,144).Similarly, no significant changes between groups were noted in delta 24-h aortic PP (-2.67±5.58 vs -0.9±4.8; p=0.130). This doctoral thesis had also several important findings concerning the effects ofdapagliflozin on ambulatory arterial stiffness parameters. 24-hour Alx(75) wassignificantly lower in the active (24.54±7.75 vs 23.25±6.83; p=0.045) and insignificantlylower (26.36±6.99 vs 25.23±6.81; p=0.217) in the control group at study-end compared with baseline. Moreover, 24-hour PWV levels reduced significantly from baseline to study-end in the active group (8.82±1.12 vs 8.66±1.10; p=0.002), but they were nodifferent in the control group (8.74±1.31 vs 8.75±1.25; p=0.693). Reductions in 24-hourAIx (-1.07±3.81 vs -1.07±5.38; p=0.999) and HR adjusted AIx [AIx(75)] levels (3A)were similar in the two groups. However, there was a significant difference in thechange of estimated 24-hour PWV (-0.16±0.32 vs 0.02±0.27; p=0.007) favoring thedapagliflozin group (3B).In a secondary analysis of the present doctoral thesis evaluating the effects ofdapagliflozin on short-term BP variability indices (SD, wSD, CV, ARV, VIM), allbrachial BP indexes were not significantly different between the baseline and study-endin any group. Aortic BPV indexes followed a similar pattern to brachial BPV indexes,again without significant differences between baseline and study-end within each of thetwo groups. The corresponding changes from baseline in the above brachial and aorticBPV indices were not different between the two study groups. No significant differenceswere observed in the dipping profiles between the baseline and study-end in any group. In addition, changes in brachial office SBP/DBP between baseline and study-endfor were statistically marginally significant in the dapagliflozin group (135.9±19.786.2±11.0 vs 131.9±15.0/83.0±9.4, p=0.065 and p=0.064, for SBP and DBPrespectively), while in the placebo group no significant changes were noted. Thechanges (Deltas) in office SBP/DBP did not differ significantly between the two groups(dapagliflozin: -4.00±19.71/-3.23±11.13 versus placebo: -3.12±22,31/-1.90±9.84,p=0.607/p=0.562).Finally, with regards to the changes in anthropometric, laboratory and safetyparameters studied in the two study groups, dapagliflozin treatment resulted in asignificant change in HbA1c of -0.57±0.74% vs -0.09±0.66% in the placebo group(p=0.002). No significant differences were observed in the lipid profile and urinaryalbumin/creatinine ratio from baseline to study-end in any group, as well as in between group comparisons. In the dapagliflozin group, a significant increase in hemoglobinvalues was observed at study-end (14.08±1.18 g / dl vs 14.69±1.26 g / dl; p <0.001). Inaddition, treatment with both dapagliflozin and placebo was associated with decreases inpatients’ body weight, BMI, and waist circumference. The overall rate of reportedadverse events was similar in dapagliflozin and placebo groups [11 patients (25.6%) inthe dapagliflozin group and 10 (23.8%) patients in the placebo group, p=0.850]. Finally,no deaths occurred during follow-up in the population studied.In conclusion, this clinical trial showed that treatment with dapagliflozin caneffectively decrease ambulatory brachial and aortic BP, as well as PWV compared withplacebo in patients with type-2 DM. Moreover, in a secondary analysis of the presentstudy it was demonstrated that treatment with dapagliflozin was not associated withsignificant effects on BPV in the same population. These findings provide clear supporton the hypothesized involvement of reductions in arterial stiffness in the beneficialeffects of SGLT-2 inhibition on reduction of heart failure events, sudden death andmortality and further support the positioning of SGLT-2 inhibitors in the recentguidelines for the management of type 2 DM [46], which specifically recommend theiruse (after metformin) in patients with cardiovascular disease, CKD or heart failure. Withregards to BPV, these results suggest that changes in short term BPV in diabetic patientsdo not accompany all modes of BP reduction, but only those where a modification ofresponsible pathogenetic mechanisms are involved. Further studies are warranted toelucidate this complex phenomena and associations, as well as assess whether SGLT-2inhibitors would affect other types of BPV in patients with T2DM
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadopoulou, Eirini
- Παπαδοπούλου, Ειρήνη
Subjects
dc:subject × 16- Δαπαγλιφλοζίνη
- Διαβήτης τύπου 2
- Κεντρική αρτηριακή πίεση
- Αρτηριακή σκληρία
- Λευκωματινουρία
- Dapagliflozin
- Diabetes mellitus
- Central blood pressure
- Arterial stiffness
- Albuminuria
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49998